Drug Approval | July 02, 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer
Imfinzi also recommended for patients with mismatch repair deficient disease
Imfinzi also recommended for patients with mismatch repair deficient disease
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Subscribe To Our Newsletter & Stay Updated
